FEISTY II

In people affected by severe trauma and critical bleeding, the timely transfusion of blood products can be lifesaving. Early replacement of fibrinogen, an important blood clotting protein, may help to reduce bleeding in these situations. The FEISTY II trial compares the two available blood products commonly used for fibrinogen replacement during major haemorrhage, with the aim to inform clinicians and policy makers about how best to deliver blood product support to improve outcomes for individual patients following major trauma. FEISTY II is a phase III randomised trial which will enrol 850 patients from Australian and New Zealand major trauma centres. Severely injured trauma patients who require blood transfusion and have evidence of low fibrinogen levels will be randomised to receive either fibrinogen concentrate or cryoprecipitate.

Fibrinogen replacement for haemorrhage following trauma is a National Blood Authority identified key evidence gap. As such, FEISTY II is well aligned with the Blood Synergy’s key objective of addressing Australia’s national transfusion research priorities. The trial is part of our Critical Bleeding stream, which focuses on ‘developing new evidence to inform and guide clinical decision-making on management of major haemorrhage and massive transfusion’. FEISTY II is managed by Monash University, and supported by an MRFF grant.

To find out more about the trial, visit FEISTY.org.au